Effect of Ramipril Therapy on Walking Ability and Quality of Life in Patients With Intermittent Claudication

A A Ahimastos; P J Walker; Christopher D Askew; A Leicht; E Pappas; P Blombery; Christopher M Reid; J Golledge; B Kingwell

doi:10.1097/01.hjh.0000420235.61512.29

Back

Effect of Ramipril Therapy on Walking Ability and Quality of Life in Patients With Intermittent Claudication

Abstract

Peer reviewed

Effect of Ramipril Therapy on Walking Ability and Quality of Life in Patients With Intermittent Claudication

A A Ahimastos, P J Walker, Christopher D Askew, A Leicht, E Pappas, P Blombery, Christopher M Reid, J Golledge and B Kingwell

Journal of Hypertension, Vol.30(Supplement 1), p.e114

Meeting of the International Society of Hypertension, 24th (Sydney, Australia, 30-Sep-2012–04-Oct-2012)

2012

DOI: https://doi.org/10.1097/01.hjh.0000420235.61512.29

Files and links (1)

url

https://doi.org/10.1097/01.hjh.0000420235.61512.29View

Published Version

Abstract

Clinical Sciences

Cardiovascular Medicine and Haematology

Background: One third of patients with peripheral artery disease (PAD) experience intermittent claudication, with the major consequence being loss of quality of life. This study was conducted to determine the efficacy of ramipril in improving walking ability and quality of life in patients with PAD. Design and Methods: 200 PAD patients (66 +/- 6 years (mean +/- SD) were randomised to receive ramipril, 10 mg once daily (n = 99) or placebo (n = 101) for 24 weeks in a double blind study. Pain free walking time (PFWT) and maximum walking time (MWT) were determined using a standard exercise treadmill test. The standard Walking Impairment Questionnaire (WIQ) and Short Form-36 (SF-36) questionnaire were administered to quantify walking ability and quality of life respectively. Results: Ramipril increased PFWT by 92% (Placebo 8.9 +/- 2 secs; Ramipril 87.2 +/- 65.8; p less than 0.0001) and MWT by 139% (Placebo 14.4 +/- 32.9 secs; Ramipril 192.7 +/- 125.9; p less than 0.0001). The treatment group reported significantly higher scores on the distance (Placebo -3.4 +/- 7.0; Ramipril 12.4 +/- 9.5; p less than 0.0001), speed (Placebo -3.2 +/- 4.5; Ramipril 11.1 +/- 7.8; p less than 0.0001) and stair climbing (Placebo -7.1 +/- 10.5; Ramipril 23.8 +/- 18.7; p less than 0.0001) subscales of the WIQ. The treatment group also reported higher scores on the physical functioning subscale of the SF-36 (Placebo -0.1 +/- 0.9, Ramipril 2.1 +/- 2.8; p less than 0.0001). Conclusions: This is thefirst adequately powered randomized trial demonstrating that ACE inhibition improves walking ability and quality of life in patients with PAD; an improvement substantially beyond that reported with conventional medical therapies.

Details

Title: Effect of Ramipril Therapy on Walking Ability and Quality of Life in Patients With Intermittent Claudication
Authors: A A Ahimastos (Author) - Baker IDI Heart and Diabetes Institute
P J Walker (Author) - University of Queensland
Christopher D Askew (Author) - Queensland University of Technology
A Leicht (Author) - James Cook University
E Pappas (Author) - James Cook University
P Blombery (Author) - Alfred Hospital
Christopher M Reid (Author) - Monash University
J Golledge (Author) - James Cook University
B Kingwell (Author) - Baker IDI Heart and Diabetes Institute
Publication details: Journal of Hypertension, Vol.30(Supplement 1), p.e114
Conference details: Meeting of the International Society of Hypertension, 24th (Sydney, Australia, 30-Sep-2012–04-Oct-2012)
Publisher: Lippincott Williams & Wilkins Ltd.
Date published: 2012
DOI: 10.1097/01.hjh.0000420235.61512.29
ISSN: 0263-6352
Organisation Unit: University of the Sunshine Coast, Queensland; School of Health and Sport Sciences - Legacy; School of Health - Sports & Exercise Science; School of Health and Behavioural Sciences - Legacy
Language: English
Record Identifier: 99448839602621
Output Type: Abstract

Metrics

4 File views/ downloads

562 Record Views